Manjit S Randhawa DO PA

Manjit S Randhawa DO PA was paid $1.35M by Medicaid between Jan 2018 and Dec 2024, across 31 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 34% of everything it billed.

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in Texas

Rank by total paid#5 of 64

Median peer was paid$7K

This provider vs. median206×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,821	$10K
2019	2,653	$9K
2020	3,598	$57K
2021	12,988	$370K
2022	12,671	$379K
2023	10,351	$318K
2024incomplete	4,290	$203K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	34%	5,366	4,988	$460K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	25%	11,172	10,332	$335K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	22%	7,671	7,135	$299K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	4.2%	3,918	3,585	$57K
80332		<1%	813	754	$13K
80361		<1%	814	753	$11K
80348		<1%	813	754	$11K
80346		<1%	813	754	$11K
80356		<1%	813	754	$10K
80354		<1%	813	754	$10K
80324		<1%	812	753	$10K
80365		<1%	813	754	$9K

19 more codes

80362		<1%	813	$9K
80321		<1%	813	$9K
80369		<1%	813	$9K
80358		<1%	813	$9K
80372		<1%	813	$8K
80367		<1%	813	$8K
80373		<1%	813	$8K
80353		<1%	813	$8K
80360		<1%	814	$7K
80368		<1%	813	$7K
80359		<1%	813	$7K
80355		<1%	813	$6K
80366		<1%	813	$5K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	3,287	$5K
80335		<1%	731	$3K
99204	Doctor's office visit, new patient (more involved)	<1%	12	$1K
80336		<1%	56	$937.75
99442		<1%	73	$23.93
99441		<1%	12	$12.33

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRANDHAWA, RITA (OFFICE MANAGER)